A Phase 3 interventional study of Admixture of propofol and etomidate at a ratio by volume of 75%/25% (P7E2) and Admixture of propofol and etomidate at a ratio by volume of 25%/75% (P2E7) in Anesthesia, Propofol Adverse Reaction and Etomidate Adverse Reaction, sponsored by University of Texas Southwestern Medical Center. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-20.
Sponsored by University of Texas Southwestern Medical Center · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 140 studies in Drug-Related Side Effects and Adverse Reactions with a site in United States — 13 open to participants now, 18 under way, 2 of them phase 3. Drug-Related Side Effects and Adverse Reactions · United States.
Among the 140 studies in Drug-Related Side Effects and Adverse Reactions with a site in United States, this one is the 39th largest by planned enrollment of the 95 interventional ones that give a count, is one of 6 that started in 2022, is one of 13 in phase 3, reaches primary completion later than 5 of the 17 other live ones, and was the 122nd registered.
449 studies on the registry are indexed under Drug-Related Side Effects and Adverse Reactions; 77 are open to participants now.
Browse Drug-Related Side Effects and Adverse Reactions studies →13 of the 140 studies in Drug-Related Side Effects and Adverse Reactions with a site in United States are open now. Recruiting first, the newest first:
Texas A&M University · Sites in United States
Ages 18–100
St. Jude Children's Research Hospital · Sites in United States
Florida Atlantic University · Sites in United States
Ages 65–110
Eli Lilly and Company · Sites in United States, Australia, China and 7 more countries
Ages 18+
Texas A&M University · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 56 Drug-Related Side Effects and Adverse Reactions studies recruiting now, 38 (68%) set no upper age limit and 15 (27%) stop at 75 or younger; 15 take children under 18; 4 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
140 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 21 · Phase 2 27 · Phase 3 14 · Phase 4 11
First in 1993; this study’s year is marked. 6 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 200 is above the median of 108 across 262 interventional studies indexed under Drug-Related Side Effects and Adverse Reactions.
Median enrollment 96 across the 95 interventional studies, 200 across the 35 observational. Of the 102 that completed or were terminated, 26 (25%) have results posted.
This tab as a report to print or save as PDF → With an account.
22 of 140 have an industry lead sponsor. The 10 most frequent:
University of Texas Southwestern Medical Center is the lead sponsor of 1,012 studies on the registry; 200 are open to participants now.
Of its 139 completed or terminated interventional studies of FDA-regulated products, 105 (76%) have results posted.
University of Texas Southwestern Medical Center has 1 study filed under Drug-Related Side Effects and Adverse Reactions — fewer than ten, so there is no comparison to draw.
6 of the studies in Drug-Related Side Effects and Adverse Reactions with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05358535Phase 3University of Texas Southwestern Medical CenterPropofol and Etomidate Admixtures Comparisons Trial (PEAC Trial) | 2027-01 |
| NCT05084196Phase 3Rutgers, The State University of New JerseyMelatonin for Prevention of Kidney Injury | 2027-06-01 |
| NCT06219720Texas A&M UniversityThe Texas Interprofessional Pharmacogenomics (IPGx) | 2026-11 |
| NCT07169851Eli Lilly and CompanyA Study to Evaluate LY3537021 for the Treatment of Nausea and Vomiting Caused by Chemotherapy in Adults With Cancer | 2026-12 |
| NCT05838638University of Central FloridaSerious Gaming for Chemotherapy-induced Nausea and Vomiting | 2027-06-30 |
Add all 6 to your calendar (.ics) → With an account.
Among the 140 studies in Drug-Related Side Effects and Adverse Reactions with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the hemodynamics and adverse event profile in comparison between two treatment arms, one using an admixture of propofol and etomidate at a ratio by volume of 25%/75% (P2E7), and one using an admixture of propofol and etomidate at a ratio by volume of 75%/25% (P7E2), for anesthesia during endoscopic procedures at the Clements University Hospital (CUH) endoscopy lab (Endo).
Procedural/Surgical anesthesia induction, administration and maintenance with propofol combined with etomidate is commonly used in routine clinical practice in patient with compromised cardiopulmonary status. However, there is no definitive trend or understanding from the literature to discern which ratio of admixture is appropriate for providing stable hemodynamics and minimizing side effects for procedural sedation in gastrointestinal endoscopy procedures. Given the increasing volume for gastrointestinal endoscopy, the increasingly older and greater chronic disease burden of the endoscopic patient population, and the increased utilization of anesthesia for endoscopic procedures this clinical trial aims to provide timely, meaningful and impactful guidance and information for the safe conductance of anesthesia in this patient population.
The objectives are to compare the treatment arms, P2E7 and P7E2, in a randomized controlled double-blind trial for anesthesia for endoscopic procedures. Comparison between an admixture of Propofol/Etomidate 75%/25% versus 25%/75% being utilized as principal anesthetic for endoscopic procedures at CUH endoscopy lab.
Propofol and etomidate can be mixed together in a syringe or similar container for up to 24 hours without adversely affecting appearance, pH, particle size and distribution, zeta potential, observation under centrifugation and drug content and impurity demonstrating the mixture to be physically and chemically compatible. Propofol and Etomidate are both FDA approved for induction and maintenance of general anesthesia in adult patients. Propofol and Etomidate in a wide ranging ratio of combinations in admixture have been utilized for general anesthesia induction and maintenance both in regular standard of care daily clinical practice and within a profound number of research trials including up to a ratio of 80% etomidate and 20 % propofol by volume. Therefore the clinical practice of etomidate and propofol in admixture for the induction and maintenance of general anesthesia in adult patients is standard of care and well founded in the anesthesiology literature. However, there are several important questions about which potential ratio of both drugs provides the best combination of favorable cardiopulmonary effects while having an acceptably low incidence of adverse effects. Thus, this current proposed trial is intended to answer several important questions on that matter.
This trial also will have actual blinding of both patients and practitioners at time of drug administration. Propofol is a white liquid and etomidate is a clear liquid. Thus, past trials where either pure drug was given in sequence or at the same time by separate syringes could not have had any blinding because of this obvious physical quality of the medications. Therefore, only a trial involving an admixture of varying ratios of both drugs could possibly hope to achieve actual blinding as is required for rigorous analysis of results without introducing the bias that comes from a lack of true blinding of patients and practitioners.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
This a prospective double blind randomized controlled clinical trial. The purpose of this study is to evaluate the hemodynamics and adverse event profile in comparison between two treatment arms, one using an admixture of propofol and etomidate at a ratio by volume of 25%/75% (P2E7), and one using an admixture of propofol and etomidate at a ratio by volume of 75%/25% (P7E2), for anesthesia during endoscopic procedures at the Clements University Hospital endoscopy lab.
Drug: Admixture of propofol and etomidate at a ratio by volume of 75%/25% (P7E2)
This a prospective double blind randomized controlled clinical trial. The purpose of this study is to evaluate the hemodynamics and adverse event profile in comparison between two treatment arms, one using an admixture of propofol and etomidate at a ratio by volume of 25%/75% (P2E7), and one using an admixture of propofol and etomidate at a ratio by volume of 75%/25% (P7E2), for anesthesia during endoscopic procedures at the Clements University Hospital endoscopy lab.
Drug: Admixture of propofol and etomidate at a ratio by volume of 25%/75% (P2E7)
Drug page: PropofolStudies of PropofolPropofol pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
The purpose of this study is to evaluate the hemodynamics and adverse event profile in comparison between two treatment arms, one using an admixture of propofol and etomidate at a ratio by volume of 25%/75% (P2E7), and one using an admixture of propofol and etomidate at a ratio by volume of 75%/25% (P7E2), for anesthesia during endoscopic procedures at the Clements University Hospital (CUH) endoscopy lab (Endo). The objectives are to compare the treatment arms, P2E7 and P7E2, in a randomized controlled double-blind trial for anesthesia for endoscopic procedures. Comparison between an admixture of Propofol/Etomidate 75%/25% versus 25%/75% being utilized as principal anesthetic for endoscopic procedures at CUH endoscopy lab.
Also known as: propofol, etomidate, P7E2, propofol 75% by volume, etomidate 25% by volume
Drug page: PropofolStudies of PropofolPropofol pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
The purpose of this study is to evaluate the hemodynamics and adverse event profile in comparison between two treatment arms, one using an admixture of propofol and etomidate at a ratio by volume of 25%/75% (P2E7), and one using an admixture of propofol and etomidate at a ratio by volume of 75%/25% (P7E2), for anesthesia during endoscopic procedures at the Clements University Hospital (CUH) endoscopy lab (Endo). The objectives are to compare the treatment arms, P2E7 and P7E2, in a randomized controlled double-blind trial for anesthesia for endoscopic procedures. Comparison between an admixture of Propofol/Etomidate 75%/25% versus 25%/75% being utilized as principal anesthetic for endoscopic procedures at CUH endoscopy lab.
Also known as: propofol, etomidate, P2E7, propofol 25% by volume, etomidate 75% by volume
Time weighted average mean arterial pressure within treatment arm
Time weighted average mean arterial pressure (every 15 minutes calculate average mean arterial pressure for that interval, then end of case calculate mean of all those means for the entire case)
Time frame: Throughout entire study estimated to take 6 to 12 months to complete
Average within treatment arm vasopressor use by number of units
Vasopressor use by number of units (1 unit of vasopressor being defined as 1 unit vasopressor = 100 mcg phenylephrine = 5 mg ephedrine = 0.5 units vasopressin = 5 mcg norepinephrine)4-9 throughout entire intraoperative period (subjects on vasopressor infusions on arrival for endoscopy will not have those vasopressor units added in UNLESS during case, anesthesia clinicians adjust the infusion based on intraoperative clinical situation as well as all bolus doses and new infusions being added as with all other subjects)
Time frame: Throughout entire study estimated to take 6 to 12 months to complete
Average within treatment arm total minutes under 92% oxygen saturation
Average within treatment arm total minutes under 92% oxygen saturation by pulse oximetry during entire case
Time frame: Throughout entire study estimated to take 6 to 12 months to complete
% of cases with any MAP below 50
% of cases with any MAP below 50
Time frame: Throughout entire study estimated to take 6 to 12 months to complete
% of cases with any MAP >60% below patient's immediate preoperative MAP
% of cases with any MAP \>60% below patient's immediate preoperative MAP
Time frame: Throughout entire study estimated to take 6 to 12 months to complete
% of cases with any treatment for Post Operative Nausea and Vomiting
% of cases with any treatment for Post Operative Nausea and Vomiting
Time frame: Throughout entire study estimated to take 6 to 12 months to complete
% of cases with any oxygen saturation event below 85% by pulse oximetry
% of cases with any oxygen saturation event below 85% by pulse oximetry
Time frame: Throughout entire study estimated to take 6 to 12 months to complete
% of cases with any rapid response or code blue event within 24 hours from anesthesia start
% of cases with any rapid response or code blue event within 24 hours from anesthesia start
Time frame: Throughout entire study estimated to take 6 to 12 months to complete
Within treatment arm % of total group with a composite MACE event in the 30 days
Within treatment arm % of total group with a composite MACE event in the 30 days after starting on day of drug administration
Time frame: Throughout entire study estimated to take 6 to 12 months to complete
Within treatment arm % of total group with a classic MACE event in the 30 days
Within treatment arm % of total group with a classic MACE event in the 30 days after starting on day of drug administration
Time frame: Throughout entire study estimated to take 6 to 12 months to complete
Average within treatment arm antiemetic use by number of doses
Average within treatment arm antiemetic use by number of doses irrespective of antiemetic drug choice
Time frame: Throughout entire study estimated to take 6 to 12 months to complete
Average within treatment arm time in minutes after dressing complete to discharge
Average within treatment arm time in minutes after dressing complete to discharge to next phase of care or to home from immediate recovery phase of care
Time frame: Throughout entire study estimated to take 6 to 12 months to complete
Within each treatment arm, average of anesthesia clinicians' assessment of quality
Within each treatment arm, average of anesthesia clinicians' assessment of quality of anesthesia during case: Poor, Below Average, Average, Above Average, Excellent (0,1,2,3,4) from all anesthesia staff then average for each treatment arm
Time frame: Throughout entire study estimated to take 6 to 12 months to complete
Within each treatment arm, average of endoscopists' assessment of quality
Within each treatment arm, average of endoscopists' assessment of quality of anesthesia during case: Poor, Below Average, Average, Above Average, Excellent (0,1,2,3,4) from all endoscopy staff then average for each treatment arm
Time frame: Throughout entire study estimated to take 6 to 12 months to complete
Within each treatment arm, average of patients' assessment of quality
Within each treatment arm, average of patients' assessment of quality of anesthesia during case: Poor, Below Average, Average, Above Average, Excellent (0,1,2,3,4) from all patients then average for each treatment arm
Time frame: Throughout entire study estimated to take 6 to 12 months to complete
Within each treatment arm, number of events of any use of 2 or more
Within each treatment arm, number of events of any use of 2 or more different (beyond study admixtures) sedative or anesthetic adjunct medications
Time frame: Throughout entire study estimated to take 6 to 12 months to complete
Within each treatment arm, number of events of any use of two or more
Within each treatment arm, number of events of any use of two or more types of antiemetic drugs
Time frame: Throughout entire study estimated to take 6 to 12 months to complete
Average time in immediate recovery area before discharge to next phase of care
Average time in immediate recovery area before discharge to next phase of care or to home
Time frame: Throughout entire study estimated to take 6 to 12 months to complete
Average time from dressing complete to modified Aldrete score >8
Average time from dressing complete to modified Aldrete score \>8
Time frame: Throughout entire study estimated to take 6 to 12 months to complete
Within each treatment arm number of composite MACE events in the 30 days
Within each treatment arm number of composite MACE events in the 30 days after starting on day of drug administration
Time frame: Throughout entire study estimated to take 6 to 12 months to complete
Within each treatment arm number of classic MACE events in the 30 days
Within each treatment arm number of classic MACE events in the 30 days after starting on day of drug administration
Time frame: Throughout entire study estimated to take 6 to 12 months to complete
Average within treatment arm total dose (mL) of admixture administered
Average within treatment arm total dose (mL) of admixture administered during entire case divided by average time from induction to dressing complete (minutes)
Time frame: Throughout entire study estimated to take 6 to 12 months to complete
Average within treatment arm total dose (mg) of etomidate during entire case
Average within treatment arm total dose (mg) of etomidate during entire case divided by average time from induction to dressing complete (minutes)
Time frame: Throughout entire study estimated to take 6 to 12 months to complete
Average within treatment arm total dose (mg) of propofol during entire case
Average within treatment arm total dose (mg) of propofol during entire case divided by average time from induction to dressing complete (minutes)
Time frame: Throughout entire study estimated to take 6 to 12 months to complete
Average within treatment arm total dose of adjunct sedatives
Average within treatment arm total dose of fentanyl, sufentanil, midazolam, diphenhydramine, ketamine, morphine, hydromorphone, dexmedetomidine, undiluted propofol, undiluted etomidate (either in mcg or mg as appropriate for each drug) divided by average time from induction to dressing complete (minutes)
Time frame: Throughout entire study estimated to take 6 to 12 months to complete
Within each treatment arm, number of events of any episode of vomiting
Within each treatment arm, number of events of any episode of vomiting
Time frame: Throughout entire study estimated to take 6 to 12 months to complete
Within each treatment arm, number of events of any complaint of nausea
Within each treatment arm, number of events of any complaint of nausea
Time frame: Throughout entire study estimated to take 6 to 12 months to complete
Within each treatment arm, number of events of any syncopal event
Within each treatment arm, number of events of any syncopal event
Time frame: Throughout entire study estimated to take 6 to 12 months to complete
Within each treatment arm, number of events of any use of one type of antiemetic drug
Within each treatment arm, number of events of any use of one type of antiemetic drug
Time frame: Throughout entire study estimated to take 6 to 12 months to complete
Within each treatment arm, number of events of any unanticipated admission
Within each treatment arm, number of events of any unanticipated admission, or transfer to higher level of care in the 24 hours after starting on day of drug administration
Time frame: Throughout entire study estimated to take 6 to 12 months to complete
Within each treatment arm, number of events of any airway adjunct usage
Within each treatment arm, number of events of any airway adjunct usage (oral airway, nasal airway, need for intermittent mask ventilation)
Time frame: Throughout entire study estimated to take 6 to 12 months to complete
Within each treatment arm, number of events of any use of any additional sedatives
Within each treatment arm, number of events of any use of any additional sedative or anesthetic adjunct medication (beyond study admixtures) during case (fentanyl, sufentanil, midazolam, diphenhydramine, ketamine, morphine, hydromorphone, dexmedetomidine, undiluted propofol, undiluted etomidate)
Time frame: Throughout entire study estimated to take 6 to 12 months to complete
Plan to share: Yes — PHI (name, date of birth, Medical Record number, phone number, email account, admission date) Demographics (Age, height, weight, BMI) Medical history Medication list Intraoperative data collection Time weighted average mean arterial pressure (every 15 minutes calculate average mean arterial pressure for that interval, then end of case calculate mean of all those means for the entire case) Area Under the Threshold for mean arterial pressure (both predefined threshold of 65 mm Hg and for 40% below patient's immediate preoperative MAP) Vasopressor use by number of units (1 unit of vasopressor being defined as 1 unit vasopressor = 100 mcg phenylephrine = 5 mg ephedrine = 0.5 units vasopressin = 5 mcg norepinephrine)
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code
Time frame: At conclusion of all data analysis and available permanently
Access criteria: Only study personnel
Started Sep 2022 (actual). Primary completion is estimated for Jan 2027, 52 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Propofol
Drug-Related Side Effects and Adverse Reactions →
University of Texas Southwestern Medical Center →